These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17828733)

  • 1. Solubility of solid solutes in HFA-134a with a correlation to physico-chemical properties.
    Hoye JA; Gupta A; Myrdal PB
    J Pharm Sci; 2008 Jan; 97(1):198-208. PubMed ID: 17828733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement and correlation of solute solubility in HFA-134a/ethanol systems.
    Hoye JA; Myrdal PB
    Int J Pharm; 2008 Oct; 362(1-2):184-8. PubMed ID: 18647644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.
    Dickinson PA; Seville PC; McHale H; Perkins NC; Taylor G
    J Aerosol Med; 2000; 13(3):179-86. PubMed ID: 11066021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy.
    Wu L; Peguin RP; da Rocha SR
    J Phys Chem B; 2007 Jul; 111(28):8096-104. PubMed ID: 17580855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers.
    Zhu B; Traini D; Chan HK; Young PM
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1625-37. PubMed ID: 24087854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPFP, a model propellant for pMDIs.
    Rogueda PG
    Drug Dev Ind Pharm; 2003 Jan; 29(1):39-49. PubMed ID: 12602491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers.
    Liao YH; Brown MB; Jones SA; Nazir T; Martin GP
    Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers.
    Gupta A; Stein SW; Myrdal PB
    J Aerosol Med; 2003; 16(2):167-74. PubMed ID: 12823910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ester group: how hydrofluoroalkane-philic is it?
    Peguin RP; Wu L; da Rocha SR
    Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in metered dose inhaler propellants].
    Chinet T
    Rev Mal Respir; 2000 Feb; 17(1):15-20. PubMed ID: 10756552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
    Hoe S; Young PM; Rogueda P; Traini D
    AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel method for the determination of solubility in aerosol propellants.
    Gupta A; Myrdal PB
    J Pharm Sci; 2004 Oct; 93(10):2411-9. PubMed ID: 15349951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of two methods to determine the solubility of compounds in aerosol propellants.
    Gupta A; Myrdal PB
    Int J Pharm; 2005 Mar; 292(1-2):201-9. PubMed ID: 15725567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The processing of nanoparticles containing protein for suspension in hydrofluoroalkane propellants.
    Nyambura BK; Kellaway IW; Taylor KM
    Int J Pharm; 2009 May; 372(1-2):140-6. PubMed ID: 19429273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
    Peyron ID; Britto IL; Benissan LB; Tardieu BZ
    Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
    Ramsdell JW; Colice GL; Ekholm BP; Klinger NM
    Ann Allergy Asthma Immunol; 1998 Dec; 81(6):593-9. PubMed ID: 9892032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of metered dose inhaler (MDI) formulations of ciclosporin.
    Marijani R; Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2007 Jan; 59(1):15-21. PubMed ID: 17227616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.